Skip Navigation

JNCI Journal of the National Cancer Institute 2000 92(2):92-94; doi:10.1093/jnci/92.2.92
© 2000 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Jordan, V. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jordan, V. C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 92, No. 2, 92-94, January 19, 2000
© 2000 Oxford University Press

EDITORIALS

How Is Tamoxifen's Action Subverted?

V. Craig Jordan

Correspondence to: V. Craig Jordan, Ph.D., D.Sc., Robert H. Lurie Comprehensive Cancer Center, Northwestern University Medical School, 303 E. Chicago Ave., Olson Pavilion #8258, Chicago, IL 60611 (e-mail: vcjordan@nwu.edu).

Tamoxifen is the endocrine therapy of choice for all stages of breast cancer (1,2). Five years of adjuvant tamoxifen improves survival if the original tumor is classified as estrogen receptor (ER) positive, but there is virtually no benefit from tamoxifen if the tumor is ER negative (2). Tamoxifen is a nonsteroidal antiestrogen (3), so, based on the simple idea that the drug would block estrogen action at the level of the tumor (4,5), it would be hard to imagine that the concept would not rapidly translate from the laboratory to the clinic. Not so. Despite the finding by Kiang and Kennedy (6) in 1977 that ER-positive . . . [Full Text of this Article]

REFERENCES


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
R. C. Dardes, R. M. O'Regan, C. Gajdos, S. P. Robinson, D. Bentrem, A. De Los Reyes, and V. C. Jordan
Effects of a New Clinically Relevant Antiestrogen (GW5638) Related to Tamoxifen on Breast and Endometrial Cancer Growth in Vivo
Clin. Cancer Res., June 1, 2002; 8(6): 1995 - 2001.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
C.-Y. Chang and D. P. McDonnell
Evaluation of Ligand-Dependent Changes in AR Structure Using Peptide Probes
Mol. Endocrinol., April 1, 2002; 16(4): 647 - 660.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C. E. Connor, J. D. Norris, G. Broadwater, T. M. Willson, M. M. Gottardis, M. W. Dewhirst, and D. P. McDonnell
Circumventing Tamoxifen Resistance in Breast Cancers Using Antiestrogens That Induce Unique Conformational Changes in the Estrogen Receptor
Cancer Res., April 1, 2001; 61(7): 2917 - 2922.
[Abstract] [Full Text]